Changing utilization of Stavudine (d4T) in HIV‐positive people in 2006–2013 in the EuroSIDA study

• DOI: 10.1111/hiv.12254
• Publication Date: 2015-05-18T11:31:13Z
• Authors: D Podlekareva; D Grint; I Karpov; A Rakmanova; K Mansinho; N Chentsova; I Zeltina; M Losso; M Parczewski; JD Lundgren; A Mocroft; O Kirk
• Keywords: Stavudine; Rate ratio; Cart

Objectives The long‐term side effects of stavudine (d4 T ) led to recommendations in 2009 phase out use this drug. We aimed describe temporal patterns d4T across Europe. Methods Patients taking combination antiretroviral therapy ( cART EuroSIDA with follow‐up after 1 J anuary 2006 were included the study. was defined as ‐containing [ plus at least two other antiretrovirals ARVs from any class] or non‐ (at three class, excluding ). Poisson regression used changes prevalence and factors associated initiating . Results A total 5850 patients receiving on January current analysis, rising 7768 2013. During time, fell 11.2% 0.7%, an overall decline 19% per 6 months [95% confidence interval CI 19–20%]. declined fastest N orthern E urope [26% (95% 23–29%) months], slowest Eastern Europe [17% 16–19%) months]. In multivariable models, new initiations decreased by 14% [adjusted incidence rate ratio aIRR 0.86; 95% 0.80–0.91]. Factors residence astern 4.31; 2.17–9.98) versus European regions HIV RNA > 400 copies/mL 3.11; 1.60–6.02) < copies/mL. Conclusions has sharply since low levels most regions; however, a but persistent level remains urope, where post are also more common. reasons for regional differences may be multifactorial, it is important ensure that all clinicians treating ‐positive aware potential harmful d4T.